Pharmaceuticals, Biotechnology and Life Sciences
Company expands expertise in TBI pathology, biomarkers and clinical development as PNT001 advances through the clinic CAMBRIDGE, Mass.–(BUSINESS WIRE)–Pinteon Therapeutics,…
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended…
U.S. Food and Drug Administration (FDA) Accepted for Review a Supplemental New Drug Application (sNDA) for RECARBRIO in Hospital-Acquired or…
1Q20 total revenues of $1,444.8 million, a 27 percent increase over 1Q19 1Q20 GAAP diluted EPS of $2.50; non-GAAP diluted…
Company to test LAU-7b’s dual pro-resolving inflammation and antiviral properties against COVID-19 MONTREAL–(BUSINESS WIRE)–Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company,…
— First-in-human trial will test the safety, pharmacokinetics and preliminary efficacy of microRNA therapeutic candidate INT-1B3 — UTRECHT, The Netherlands–(BUSINESS…
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
Arcus Biosciences Net loss was $27.8 million for the three months ended March 31, 2020, compared to $17.7 million for the same period in the prior year. The increase in net loss as compared to the prior period was primarily attributable to an increase in operating expenses.
Clovis reported a net loss for the first quarter of 2020 of $99.3 million, or ($1.39) per share, compared to the net loss for the first quarter of 2019 which was $86.4 million, or ($1.63) per share. Net loss for the first quarter of 2020 included share-based compensation expense of $13.0 million, compared to $13.6 million for the first quarter of 2019.
Sanofi and Regeneron plan to submit this year their product Libtayo, which has shown in a pivotal trial with certain patients with advanced basal cell carcinoma, that it has meaningful and durable responses.